EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-SA 4.0

Nirsevimab for Prevention of Respiratory Syncytial Virus Lower Respiratory Tract Infection in Infants: A Systematic Review of Randomized Controlled Trials

Dwi Novilolita, Vistaria Furkano, Sakinah Shadrina

Prima Journal of Medical Sciences · 30.09.2026 · 1 (2) · 133-138

DOI: 10.35730/y3teyv85 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Prima Journal of Medical Sciences, online erschienen am 30.09.2026. Verfasst von Dwi Novilolita und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection (LRTI) and hospitalization in infants. Nirsevimab is a long-acting monoclonal antibody given as a single dose. This systematic review summarizes its efficacy and safety in randomized controlled trials (RCTs).

Methods

RCTs of nirsevimab in infants, reporting medically attended RSV LRTI or hospitalization, were eligible. Data were extracted and synthesized without meta-analysis following the SWiM reporting guideline, with qualitative risk-of-bias appraisal using RoB 2 domains.

Findings

Three RCTs (a phase 2b trial, MELODY, and HARMONIE; 11,001 randomized infants) were included. Efficacy against medically attended RSV LRTI was 70.1% (95% CI 52.3–81.2) in the phase 2b trial, 74.5% (95% CI 49.6–87.1) in MELODY, and 83.2% (95% CI 67.8–92.0) against RSV LRTI hospitalization in HARMONIE. Serious adverse events were similar between groups in the placebo-controlled trials.

Conclusion

Nirsevimab reduced RSV LRTI in infants across three trials, with an acceptable short-term safety profile. Data from Indonesia and tropical settings were not found.

Zitieren

APA

Novilolita, D., Furkano, V., & Shadrina, S. (2026). Nirsevimab for Prevention of Respiratory Syncytial Virus Lower Respiratory Tract Infection in Infants: A Systematic Review of Randomized Controlled Trials. Prima Journal of Medical Sciences, 1(2), 133-138. https://doi.org/10.35730/y3teyv85

Vancouver

Novilolita D, Furkano V, Shadrina S. Nirsevimab for Prevention of Respiratory Syncytial Virus Lower Respiratory Tract Infection in Infants: A Systematic Review of Randomized Controlled Trials. Prima Journal of Medical Sciences. 2026;1(2):133-138. doi:10.35730/y3teyv85

BibTeX
@article{Novilolita2026,
  author = {Novilolita, Dwi and Furkano, Vistaria and Shadrina, Sakinah},
  title = {Nirsevimab for Prevention of Respiratory Syncytial Virus Lower Respiratory Tract Infection in Infants: A Systematic Review of Randomized Controlled Trials},
  journal = {Prima Journal of Medical Sciences},
  year = {2026},
  volume = {1},
  number = {2},
  pages = {133--138},
  doi = {10.35730/y3teyv85}
}
Kostenlos starten →